Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec 12;13(12):OF9.
doi: 10.1158/2159-8290.CD-ND2023-0012.

EGFR-Mutant NSCLC: Spotlight on Amivantamab

No authors listed
Comment

EGFR-Mutant NSCLC: Spotlight on Amivantamab

No authors listed. Cancer Discov. .

Abstract

Data from three phase III trials-PAPILLON, MARIPOSA, and MARIPOSA-2-highlight amivantamab, an EGFR-MET bispecific antibody, as a potential contender as a standard treatment for EGFR-mutant non-small cell lung cancer. Amivantamab paired with chemotherapy is a superior first-line option for patients with exon 20-mutated disease. Beyond this subset, compared with standard osimertinib, the combination with or without lazertinib also boosted progression-free survival, albeit at the cost of added toxicity.

PubMed Disclaimer

Comment on

  • Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.

MeSH terms